NewLink, Genentech Hook Up | Chemical & Engineering News
Volume 92 Issue 43 | p. 15 | Concentrates
Issue Date: October 27, 2014

NewLink, Genentech Hook Up

Department: Business
Keywords: immunotherapy, antibodies, licensing

Immunotherapeutics specialist NewLink Genetics has licensed NLG919, its indoleamine 2,3-dioxygenase (IDO) pathway inhibitor, to Genentech. NewLink will receive $150 million up front and is eligible to receive milestone payments and royalties. Genentech also will fund future R&D and manufacturing. IDO pathway inhibitors are small-molecule immune checkpoint inhibitors that can complement Genentech antibodies being developed as immunotherapies.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment